Mallinckrodt uses cookies to improve and analyze site functionality. Some aspects of the site may not function properly without cookies enabled. To learn more about how we use cookies and how you can change your cookies settings, please read our Privacy Policy. By continuing to browse the site, you are agreeing to accept our use of cookies.
Our goal is to become one of the leading specialty pharmaceutical companies developing, registering and supporting valuable medicines that significantly improve patients' lives.
Since 2010, Mallinckrodt has received U.S. Food and Drug Administration approval for 14 drugs across our portfolio. Today, we have more than two dozen products in development. We are also executing key company-sponsered studies directed at defining the efficacy, safety, and health economic benefits of our key products.
Mallinckrodt's exceptional strength in drug reformulation has bolstered our position as an industry leader in the development and manufacturing of specialty generic drugs. This continues to be a significant R&D focus.
From philanthropic efforts to advocacy initiatives, we are living our values throughout our communities.
Learn How